European Patent Office Grants Biomoda Patent

The European Patent Office (EPO) has granted Biomoda, Inc.’s patent application for using our proprietary CyPath® technology to detect cancer and pre-cancerous cells in body fluid and tissue samples. Titled “Composition and Methods for Detecting Pre-Cancerous Conditions In Cell And Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenol) Porphine,” EPO patent 1364044 is similar to…

Read more »

Biomoda Files New Patent Application To Optimize CyPath® Assay

Albuquerque, NM – Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) filed an application for a new U.S. Patent that refines the use of fluorescent microscopy to increase the accuracy, sensitivity and specificity of the CyPath® diagnostic assay for lung cancer. “This patent is based on a proprietary solid-state, diode-based light source for fluorescent microscopy…

Read more »

Shareholder Meeting

Biomoda Shareholder Presentation Meeting Results of Shareholder Meeting Proposal 1 The Company’s stockholders elected four individuals to the Board of Directors. Name                                          VotesFor                         Votes Withheld John J. Cousins                          162,513,010                            656,872 Maria Zannes                             162,800,016                            369,866 Lewis White                               162,619,007                            550,875 David Lambros                           162,619,007                            550,875  Proposal 2 The Company’s stockholders…

Read more »

European Patent Office To Grant Biomoda Patent

Albuquerque, NM (Aug. 2, 2011) – Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) (www.biomoda.com) received notification from the European Patent Office (EPO) of its intention to grant the company’s patent application related to a method of using Biomoda’s proprietary porphyrin-based compound to detect cancer and pre-cancerous cells in body fluid and tissue samples. “According…

Read more »

Biomoda Retires Notes Early

Albuquerque, NM  – Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) (www.biomoda.com) today announced that it has retired $560,000 in principal amount, plus all interest, of convertible debentures issued in September 2010.  The convertible debentures were scheduled to mature on August 31, 2011. The institutional investors holding the notes completed the conversion of the notes…

Read more »

Biomoda, Inc.

Biomoda is a cancer diagnostics company focused on the development of an inexpensive, simple, highly accurate in-vitro test for the early detection of lung cancer. The CyPath® assay is based upon Biomoda's patent estate centered on molecular marker technology originally developed at the Los Alamos National Laboratory.

Useful Links